AbCellera Biologics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Shareholders held by AbCellera Biologics Inc. on June 11, 2026. The record date for the meeting was April 15, 2026, with 305,264,947 common shares outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Shareholders voted on three proposals, all of which were approved:
- Proposal 1 (Election of Directors): John S. Montalbano, CFA, and Stephen R. Quake, D.Phil., were elected as Class III directors for a three-year term expiring in 2029.
- Proposal 2 (Auditor Ratification): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- Proposal 3 (Say-on-Pay): The compensation of named executive officers was approved on a non-binding advisory basis.
Voting Breakdown
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Proposal 1 (Directors) | 141,430,732 (Montalbano) 149,019,960 (Quake) |
12,723,342 (Montalbano) 5,113,056 (Quake) |
45,898 (Montalbano) 66,956 (Quake) |
36,576,359 |
| Proposal 2 (Auditor) | 189,927,972 | 552,429 | 295,930 | N/A |
| Proposal 3 (Say-on-Pay) | 142,831,950 | 10,932,105 | 435,917 | 36,576,359 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the three-year director tenure for the newly elected Class III directors.
- Review the Definitive Proxy Statement filed on April 29, 2026, for detailed descriptions of the proposals and executive compensation.
- Note the significant number of broker non-votes (36,576,359 shares) on Proposals 1 and 3, which may indicate passive institutional holdings.
- Confirm the fiscal year-end date of December 31, 2026, for the ratified auditor engagement.